09:08 AM EDT, 10/16/2025 (MT Newswires) -- Grail (GRAL), Samsung C&T, and Samsung Electronics said Thursday they have signed a binding letter of intent for a strategic collaboration to bring Grail's Galleri multi-cancer early detection test to certain Asian markets.

Samsung C&T and Samsung Electronics also agreed to invest $110 million into Grail at the price of $70.05 per share of common stock, according to the statement.

Under the agreement, Samsung C&T and Grail will work as exclusive partners to commercialize Galleri test in South Korea, with possible expansion into Japan and Singapore, the companies said.

Meanwhile, Samsung Electronics and Grail will explore a potential collaboration supporting longitudinal genomic-lifestyle clinical research, and integrating Samsung Electronics' health data platform with Grail's technologies, the companies said.

The companies plan to sign definitive agreements and close Samsung's equity investment into Grail in early 2026, the companies said.

Shares of Grail were up over 14% in recent Thursday premarket activity.